Klotho Neurosciences Files Q2 2025 10-Q
Ticker: GRMLW · Form: 10-Q · Filed: Aug 18, 2025 · CIK: 1907223
Sentiment: neutral
Topics: 10-Q, company-information, quarterly-report
TL;DR
Klotho Neurosciences (formerly ANEW Medical) filed its Q2 2025 10-Q. Check financials.
AI Summary
Klotho Neurosciences, Inc. filed its quarterly report for the period ending June 30, 2025. The company, formerly known as ANEW Medical, Inc. and Redwoods Acquisition Corp., is in the biological products sector. Its principal executive offices are located at 13576 Walnut Street, Suite A, Omaha, NE 68144.
Why It Matters
This filing provides investors with an update on Klotho Neurosciences' financial performance and operational status for the second quarter of 2025.
Risk Assessment
Risk Level: low — This is a routine quarterly filing providing basic company information and financial reporting, with no immediate high-risk indicators.
Key Players & Entities
- Klotho Neurosciences, Inc. (company) — Registrant
- June 30, 2025 (date) — Quarterly period end date
- ANEW Medical, Inc. (company) — Former company name
- Redwoods Acquisition Corp. (company) — Former company name
- 13576 Walnut Street, Suite A, Omaha, NE 68144 (address) — Business and mail address
- 001-41340 (other) — SEC file number
FAQ
What is the primary business of Klotho Neurosciences, Inc.?
Klotho Neurosciences, Inc. is in the business of Biological Products (No Diagnostic Substances), with SIC code 2836.
When was the company formerly known as ANEW Medical, Inc.?
The company changed its name from ANEW Medical, Inc. on June 24, 2024.
What is the SEC file number for Klotho Neurosciences, Inc.?
The SEC file number for Klotho Neurosciences, Inc. is 001-41340.
Where are Klotho Neurosciences, Inc.'s principal executive offices located?
The company's business and mail address is 13576 Walnut Street, Suite A, Omaha, NE 68144.
For what period is this 10-Q filing reporting?
This 10-Q filing is for the quarterly period ended June 30, 2025.
Filing Stats: 4,616 words · 18 min read · ~15 pages · Grade level 16.7 · Accepted 2025-08-18 06:12:36
Key Financial Figures
- $0.0001 — hares of the registrant's common stock, $0.0001 par value, issued and outstanding. KLO
Filing Documents
- ea0253157-10q_klotho.htm (10-Q) — 635KB
- ea025315701ex31-1_klotho.htm (EX-31.1) — 10KB
- ea025315701ex31-2_klotho.htm (EX-31.2) — 10KB
- ea025315701ex32-1_klotho.htm (EX-32.1) — 4KB
- ea025315701ex32-2_klotho.htm (EX-32.2) — 4KB
- 0001213900-25-077684.txt ( ) — 5060KB
- klto-20250630.xsd (EX-101.SCH) — 51KB
- klto-20250630_cal.xml (EX-101.CAL) — 29KB
- klto-20250630_def.xml (EX-101.DEF) — 270KB
- klto-20250630_lab.xml (EX-101.LAB) — 441KB
- klto-20250630_pre.xml (EX-101.PRE) — 275KB
- ea0253157-10q_klotho_htm.xml (XML) — 523KB
FINANCIAL INFORMATION
PART I. FINANCIAL INFORMATION 1 ITEM 1.
Financial Statements
Financial Statements 1 Condensed Consolidated Balance Sheets at June 30, 2025 (Unaudited) and December 31, 2024 1 Unaudited Condensed Consolidated Statements of Operations for the Three and Six Months Ended June 30, 2025 and 2024 2 Unaudited Condensed Consolidated Statements of Changes in Stockholders' Equity (Deficit) for the Three and Six Months Ended June 30, 2025 and 2024 3 Unaudited Condensed Consolidated Statements of Cash Flows for the Six Months Ended June 30, 2025 and 2024 4 Notes to Unaudited Condensed Consolidated Financial Statements 5 ITEM 2.
Management's Discussion and Analysis of Financial Condition and Results of Operations
Management's Discussion and Analysis of Financial Condition and Results of Operations 21 ITEM 3.
Quantitative and Qualitative Disclosures about Market Risk
Quantitative and Qualitative Disclosures about Market Risk 24 ITEM 4.
Controls and Procedures
Controls and Procedures 25
OTHER INFORMATION
PART II. OTHER INFORMATION 26 ITEM 1.
Legal Proceedings
Legal Proceedings 26 ITEM 1A.
Risk Factors
Risk Factors 26 ITEM 2. Unregistered Sales of Equity Securities, Use of Proceeds, and Issuer Purchases of Equity Securities 2 6 ITEM 3. Defaults Upon Senior Securities 26 ITEM 4. Mine Safety Disclosures 26 ITEM 5. Other Information 26 ITEM 6. Exhibits 26
FINANCIAL INFORMATION
PART I. FINANCIAL INFORMATION
Financial Statements
Item 1. Financial Statements KLOTHO NEUROSCIENCES, INC. CONDENSED CONSOLIDATED BALANCE SHEETS June 30, 2025 December 31, 2024 (Unaudited) ASSETS Current assets: Cash and cash equivalents $ 8,430,946 $ 63,741 Prepaid expenses 115,386 94,070 Total current assets 8,546,332 157,811 Other assets: Licenses 2,251,134 2,251,134 Patents 48,420 48,420 Total other assets 2,299,554 2,299,554 Total assets $ 10,845,886 $ 2,457,365 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable $ 12,631 $ 63,686 Accrued expenses 50,331 912,095 Notes payable to related parties - 31,000 Notes payable - 240,753 Total current liabilities 62,962 1,247,534 Warrant liability 132,447 24,486 Total liabilities 195,409 1,272,020 Commitments and contingencies (Note 10) STOCKHOLDERS' EQUITY Preferred stock, par value $ 0.0001 , 100,000,000 shares authorized; 500 and 0 issued and outstanding as of June 30, 2025 and December 31, 2024, respectively - - Common stock, par value $ 0.0001 , 1,000,000,000 shares authorized; 52,703,070 and 27,080,915 shares issued and outstanding as of June 30, 2025 and December 31, 2024, respectively 5,270 2,708 Additional paid-in capital 27,535,219 11,745,436 Accumulated deficit ( 16,890,012 ) ( 10,562,799 ) Total stockholders' equity 10,650,477 1,185,345 Total liabilities and stockholders' equity $ 10,845,886 $ 2,457,365 See accompanying notes to the unaudited condensed consolidated financial statements. 1 KLOTHO NEUROSCIENCES, INC. UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS For the Three Months Ended June 30, For the Six Months Ended June 30, 2025 2024 2025 2024 Operating expenses: Professional fees $ 924,580 $ 355,752 $ 1,661,266 $ 731,348 General and administrative 339,377 2,341 694,159 48,790 Research and development 238,700 - 238,700 - Share-based compensation 390,195 37,514 885,695 37,514 Tot
FINANCIAL STATEMENTS
FINANCIAL STATEMENTS NOTE 1 — ORGANIZATION AND BUSINESS DESCRIPTION Klotho Neurosciences, Inc. ("The Company" or "Klotho"), formerly known as ANEW Medical, Inc., develops essential medicines for the treatment of chronic diseases – cancer, cardiovascular, and neurodegenerative disorders. The Company currently has acquired two licensed platforms: a generic drug portfolio and a biosimilar biologics platform that uses biologic therapies to treat cancer, and a proprietary, patented gene therapy platform that uses a gene therapy approach to introduce a therapeutic protein called "Klotho" inside the body to treat neurodegenerative diseases. On September 12, 2022, the Company acquired five market-approved anti-cancer drugs approved for sale in Germany. The Market Authorizations (MA's) are for four of the drugs that comprise the "FOLFOX" and "FOLFIRI" multi-drug regimens used in treatment of metastatic colorectal and gastric cancer and in two of the drugs that are used to treat metastatic lung cancer. The drugs are important in the treatment of many solid tumors in both childhood and adult cancers. Previously, the Company acquired two off-patent bio generic antibodies from Reliance Life Sciences (RLS), the life science arm of Reliance Industries Pvt Ltd. of Navi Mumbai, India. Effective July 24, 2024, the Company changed its legal name from ANEW Medical, Inc. to Klotho Neurosciences, Inc. This name change was approved by the Company's Board of Directors to better reflect the strategic focus of its proprietary products. Throughout these financial statements, references to the "Company" refer to Klotho Neurosciences, Inc., formerly known as ANEW Medical, Inc (ANEW). Under certain circumstances, references to ANEW have remained useful when describing the sequence of events that occurred during the merger between Redwoods and ANEW. Business Combinations As of May 30, 2023, Redwoods Acquisition Corp., a Delaware corporation and a special purpose acquisition company ("Red